FDA Approval Summary: Futibatinib for Unresectable Advanced or Metastatic, Chemotherapy Refractory Intrahepatic Cholangiocarcinoma with FGFR2 Fusions or Other Rearrangements
FDA批准摘要:Futibatinib用于治疗不可切除的晚期或转移性、化疗难治性肝内胆管癌,伴有FGFR2融合或其他重排
期刊:Clinical Cancer Research
影响因子:10.2
doi:10.1158/1078-0432.CCR-23-1042
Gandhy, Shruti U; Casak, Sandra J; Mushti, Sirisha L; Cheng, Joyce; Subramaniam, Sriram; Zhao, Hong; Zhao, Miao; Bi, Youwei; Liu, Guansheng; Fan, Jianghong; Adeniyi, Oluseyi; Charlab, Rosane; Kufrin, Dubravka; Thompson, Matthew D; Jarrell, Kristin; Auth, Doris; Lemery, Steven J; Pazdur, Richard; Kluetz, Paul G; Fashoyin-Aje, Lola A